NRIP2

Across TCGA pan-cancer cohorts, NRIP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NRIP2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NRIP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NRIP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, UCEC, and CCRCC are the cancer types where NRIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.857	0.582	<.001	70	view →
UCEC	OS	Quartile	III,IV	0.329	1.000	.024	20	view →
CCRCC	DFS	Quartile	III,IV	0.896	0.411	.006	12	view →
HNSC	OS	Median	IV	0.936	0.768	.010	8	view →
LSCC	DFS	Median	III,IV	0.856	0.487	.025	3	view →
GBM	OS	Median	All	0.295	0.461	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NRIP2–PDAC (DFS)

Open the PDAC breakdown →